CORDIS
EU research results

CORDIS

English EN
Novel magnetic nanostructures for medical applications

Novel magnetic nanostructures for medical applications

Objective

MAGNAMED designs, fabricates, and assesses novel magnetic nanostructures (MNS) with unique spin configurations for innovative diagnostics and therapy techniques. An early stage detection and an effective treatment are keystones to reduce cancer mortality. Current clinical procedures fail to detect small concentration of tumoral biomarkers. Magnetic nanoparticles (MNP), like beads, have attracted much attention for their capability to improve cancer detection limits and treatment technologies. However, there are several limitations to the use of MNP. As an emerging alternative, MNS are being explored. Unlike MNP, MNS (e.g. nanodisks) present a planar shape with novel properties for diagnosis: high magnetic moment and large size, which can significantly improve the sensor sensitivity, and for therapy: due to their planar shape, alternate magnetic fields provoke a magneto-mechanical action on the cell membrane that triggers cell death. The efficiency of MNS in these two medical applications has not been investigated yet for MNS at the nanometer scale. The challenge of this project is to produce MNS with nanometer dimensions suitable for medical applications. Several lithography techniques will be used to fabricate MNS in vortex and antiferromagnetic spin configurations covering a broad size range (40 to 4000 nm). After functionalization, MNS will be exploited in: (i) Diagnostics, using giant magnetoresistance (GMR) sensors for the detection of tumoral biomarkers (dermcidin and carcinoembryonic antigen), and (ii) Therapy, effectiveness of tumoral cell annihilation by the magneto-mechanical action of MNS will be evaluated in vitro assays of melanoma and colorectal cancer cells. MAGNAMED is a cross-sectoral and interdisciplinary project involving Physics, Chemistry and Medicine. Findings will have a medium-term impact on the European strategy for early stage detection of cancer and a long-term impact on the development of novel and groundbreaking therapeutics techniques.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSIDAD DEL PAIS VASCO/ EUSKAL HERRIKO UNIBERTSITATEA

Address

Barrio Sarriena S N
48940 Leioa

Spain

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 310 500

Participants (7)

Sort alphabetically

Sort by EU Contribution

Expand all

IMG PHARMA BIOTECH SOCIEDAD LIMITADA

Spain

EU Contribution

€ 54 000

NANOVEX BIOTECHNOLOGIES SL

Spain

EU Contribution

€ 22 500

UNIVERSIDAD COMPLUTENSE DE MADRID

Spain

EU Contribution

€ 27 000

INESC MICROSISTEMAS E NANOTECNOLGIAS-INSTITUTO DE ENGENHARIA DE SISTEMAS DE COMPUTADORES PARA OS MICROSISTEMAS E AS NANOTECNOLOGIAS

Portugal

EU Contribution

€ 99 000

UNIVERSIDADE DO PORTO

Portugal

EU Contribution

€ 148 500

VIENNA BIOCENTER CORE FACILITES GMBH

Austria

EU Contribution

€ 117 000

ICETA INSTITUTO DE CIENCIAS, TECNOLOGIAS E AGROAMBIENTE DA UNIVERSIDADE DO PORTO

Portugal

EU Contribution

€ 67 500

Partners (7)

Sort alphabetically

Expand all

UNIVERSIDAD DE SANTIAGO DE CHILE

COMISION NACIONAL DE ENERGIA ATOMICA

COMISSAO NACIONAL DE ENERGIA NUCLEAR- CENTRO DE DESENVOLVIMENTO DA TECNOLOGIA NUCLEAR

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

THE UNIVERSITY OF TEXAS SYSTEM

UNIVERSIDAD TECNICA FEDERICO SANTA MARIA

UNIVERSIDADE ESTADUAL DE CAMPINAS

Project information

Grant agreement ID: 734801

Status

Ongoing project

  • Start date

    1 April 2017

  • End date

    31 March 2021

Funded under:

H2020-EU.1.3.3.

  • Overall budget:

    € 846 000

  • EU contribution

    € 846 000

Coordinated by:

UNIVERSIDAD DEL PAIS VASCO/ EUSKAL HERRIKO UNIBERTSITATEA

Spain